Crispr Therapeutics Ag Stock Current Liabilities
| 1CG Stock | 40.80 0.00 0.00% |
CRISPR Therapeutics AG fundamentals help investors to digest information that contributes to CRISPR Therapeutics' financial success or failures. It also enables traders to predict the movement of CRISPR Stock. The fundamental analysis module provides a way to measure CRISPR Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CRISPR Therapeutics stock.
CRISPR |
CRISPR Therapeutics AG Company Current Liabilities Analysis
CRISPR Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, CRISPR Therapeutics AG has a Current Liabilities of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Current Liabilities (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
CRISPR Fundamentals
| Current Valuation | 2.16 B | |||
| Price To Book | 6.67 X | |||
| Price To Sales | 1,731 X | |||
| Revenue | 436 K | |||
| EBITDA | (648.99 M) | |||
| Net Income | (650.17 M) | |||
| Cash Flow From Operations | (495.74 M) | |||
| Market Capitalization | 4.99 B | |||
| Total Asset | 2.24 B | |||
| Net Asset | 2.24 B |
About CRISPR Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CRISPR Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CRISPR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CRISPR Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for CRISPR Stock Analysis
When running CRISPR Therapeutics' price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.